Phase II/III randomized trial of TCH346 in patients with ALS

• Published in: Neurology Vol. 69; no. 8; p. 776
• Main Authors: Miller, R, Bradley, W, Cudkowicz, M, Hubble, J, Meininger, V, Mitsumoto, H, Moore, D, Pohlmann, H, Sauer, D, Silani, V, Strong, M, Swash, M, Vernotica, E
• Format: Journal Article
• Language: English
• Published: United States 21.08.2007
• Subjects: Administration, Oral; Adult; Aged; Aged, 80 and over; Amyotrophic Lateral Sclerosis - drug therapy; Apoptosis - drug effects; Apoptosis - physiology; Central Nervous System - drug effects; Central Nervous System - enzymology; Central Nervous System - physiopathology; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors - administration & dosage; Enzyme Inhibitors - adverse effects; Female; Glyceraldehyde-3-Phosphate Dehydrogenases - antagonists & inhibitors; Glyceraldehyde-3-Phosphate Dehydrogenases - metabolism; Humans; Male; Middle Aged; Nerve Degeneration - drug therapy; Nerve Degeneration - enzymology; Nerve Degeneration - prevention & control; Neuroprotective Agents - administration & dosage; Neuroprotective Agents - adverse effects; Oxepins - administration & dosage; Oxepins - adverse effects; Placebo Effect; Treatment Failure
• ISSN: 1526-632X
• DOI: 10.1212/01.wnl.0000269676.07319.09

TCH346 exerts antiapoptotic effects by binding to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and blocking the apoptotic pathway in which GAPDH is involved. Apoptosis is considered to be a key pathogenic mechanism in neurodegenerative diseases including ALS. Patients were randomly assigned in a double-blind fashion to receive either placebo or one of four doses of TCH346 (1.0, 2.5, 7.5, or 15 mg/day) administered orally once daily for at least 24 weeks. The primary outcome measure was the rate of change in the revised ALS functional rating scale (ALSFRS-R). The trial design included a 16-week lead-in phase to determine each patient's rate of disease progression. The between treatment comparison was adjusted for the individual pretreatment rates of progression. The study was powered to detect a 25% reduction in the rate of decline of the ALSFRS-R as compared with placebo. Secondary outcome measures included survival, pulmonary function, and manual muscle testing (MMT). Five hundred ninety-one patients were enrolled at 42 sites in Europe and North America. There were no differences in baseline variables. There were no significant differences between placebo and active treatment groups in the mean rate of decline of the ALSFRS-R or in the secondary outcome measures (survival, pulmonary function, and MMT). The trial revealed no evidence of a beneficial effect of TCH346 on disease progression in patients with ALS.